These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32362146)

  • 1. GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition.
    Yao XM; Niu FJ; Kong L; Cai FY; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
    Drug Dev Ind Pharm; 2020 Jun; 46(6):916-930. PubMed ID: 32362146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
    Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
    Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
    [No Abstract]   [Full Text] [Related]  

  • 3. Dioscin suppresses TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion.
    Lim WC; Kim H; Kim YJ; Choi KC; Lee IH; Lee KH; Kim MK; Ko H
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3342-3348. PubMed ID: 28610976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.
    Ju RJ; Cheng L; Peng XM; Wang T; Li CQ; Song XL; Liu S; Chao JP; Li XT
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):616-628. PubMed ID: 29381101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
    Fu M; Tang W; Liu JJ; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    J Drug Target; 2020 Mar; 28(3):245-258. PubMed ID: 31462111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
    Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
    J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
    Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
    Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dioscin Inhibits the Invasion and Migration of Hepatocellular Carcinoma HepG2 Cells by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition.
    Chen B; Zhou S; Zhan Y; Ke J; Wang K; Liang Q; Hou Y; Zhu P; Ao W; Wei X; Xiao J
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31197076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrin Modified Dioscin Loaded PEGylated Liposomes: Characterization and
    Wang Y; Yang Y; Yu Y; Li J; Pan W; Yang X; Zhang Z; Jiang S; Yang X; Wang X
    J Nanosci Nanotechnol; 2020 Mar; 20(3):1321-1331. PubMed ID: 31492291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
    Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
    J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
    Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
    Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
    Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
    Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluplus/TPGS mixed micelles for dioscin delivery in cancer therapy.
    Zhao J; Xu Y; Wang C; Ding Y; Chen M; Wang Y; Peng J; Li L; Lv L
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1197-1204. PubMed ID: 28300426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.
    Guo J; Zhou J; Ying X; Men Y; Li RJ; Zhang Y; Du J; Tian W; Yao HJ; Wang XX; Ju RJ; Lu WL
    J Pharm Pharm Sci; 2010; 13(2):136-51. PubMed ID: 20816001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound-Targeted Microbubble Destruction (UTMD) Combined with Liposome Increases the Effectiveness of Suppressing Proliferation, Migration, Invasion, and Epithelial- Mesenchymal Transition (EMT) via Targeting Metadherin (MTDH) by ShRNA.
    Xu J; Wang Y; Li Z; Wang Q; Zhou X; Wu W
    Med Sci Monit; 2019 Apr; 25():2640-2648. PubMed ID: 30969950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.
    Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF
    J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connexin 43 upregulation by dioscin inhibits melanoma progression via suppressing malignancy and inducing M1 polarization.
    Kou Y; Ji L; Wang H; Wang W; Zheng H; Zou J; Liu L; Qi X; Liu Z; Du B; Lu L
    Int J Cancer; 2017 Oct; 141(8):1690-1703. PubMed ID: 28677156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dioscin suppresses human laryngeal cancer cells growth via induction of cell-cycle arrest and MAPK-mediated mitochondrial-derived apoptosis and inhibition of tumor invasion.
    Si L; Zheng L; Xu L; Yin L; Han X; Qi Y; Xu Y; Wang C; Peng J
    Eur J Pharmacol; 2016 Mar; 774():105-17. PubMed ID: 26849940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anticancer potential of steroidal saponin, dioscin, isolated from wild yam (Dioscorea villosa) root extract in invasive human breast cancer cell line MDA-MB-231 in vitro.
    Aumsuwan P; Khan SI; Khan IA; Ali Z; Avula B; Walker LA; Shariat-Madar Z; Helferich WG; Katzenellenbogen BS; Dasmahapatra AK
    Arch Biochem Biophys; 2016 Feb; 591():98-110. PubMed ID: 26682631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition.
    Cai FY; Yao XM; Jing M; Kong L; Liu JJ; Fu M; Liu XZ; Zhang L; He SY; Li XT; Ju RJ
    J Liposome Res; 2021 Jun; 31(2):113-129. PubMed ID: 32200703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.